[Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].
Our results were similar to the previous period. The number of rebiopsies was essentially unchanged compared to the 2019-2021 period, which may be the main reason why we were able to identify the mutation in a lower percentage compared to the T790M hit rate described in the literature.
Authors
- Zsuzsanna Szalai (ORCID: https://orcid.org/0000-0001-7012-2060)
- János Szőke
- Krisztina Bogos
- Helga Engi
- László Báthory-Fülöp
- Zsolt Pápai (ORCID: https://orcid.org/0000-0003-3369-9949)
- Judit Moldvay (ORCID: https://orcid.org/0000-0001-9425-1748)
- Andrea Kohánka (ORCID: https://orcid.org/0000-0001-8834-4657)
- Erika Tóth (ORCID: https://orcid.org/0000-0003-2669-6328)
- Eszter Tanács-Bencze
Institutions
- Országos Korányi Tbc és Pulmonológiai Intézet (HU)
Publication Details
- Journal
- PubMed
- Published
- 2024-12-10
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article